The new generation weight-loss drug developed by the U.S. biotechnology company Metsera, Inc. (MTSR) demonstrated excellent tolerability in a mid-stage clinical trial, with only about 3% of participants withdrawing from the study. This low dropout rate is significantly better than other similar drug trials, which often see participants discontinuing due to side effects. Professor John Buse from the University of North Carolina School of Medicine, who presented the trial at the Obesity Week conference in Atlanta, noted that its tolerability profile was outstanding. Study data showed that after 28 weeks of once-weekly injectable treatment, participants experienced an average weight reduction of 14.1%, with low rates of nausea and vomiting. The weight loss efficacy was comparable to that of the current market leader, Eli Lilly’s Zepbound. Metsera further revealed that participants’ weight continued to decrease throughout the trial without reaching a plateau, and that side effects could be further improved by starting with a low dose and gradually increasing it.
These positive clinical results have significantly increased Metsera’s appeal, triggering a fierce bidding war between Pfizer and Novo Nordisk. This acquisition battle began with private negotiations in January of this year and recently became public. Novo Nordisk took the initiative by first submitting an acquisition proposal to Metsera worth approximately $6 billion. The bidding quickly escalated, with both parties successively raising their offers. It was disclosed that Pfizer increased its offer to match Novo Nordisk’s $10 billion bid, after which Novo Nordisk again raised its offer to an even higher level. Its CEO, Mike Doustaler, publicly stated that their current offer is more advantageous and urged competitors to put real money on the table. Public filing records show that at least 16 offers have been exchanged between the two companies. Driven by this bidding war, Metsera’s stock price has surged significantly, with a recent single-day increase of over 13%, closing at $81. The stock has gained more than 55% since Novo Nordisk’s public tender offer.
The core focus of the bidding war is Metsera’s highly valuable R&D pipeline. Its lead candidate is a weekly injectable therapy, but the company plans to explore the possibility of developing it into a monthly injection, which could position it to compete directly with Amgen’s MariTide. Furthermore, other candidate drugs in Metsera’s pipeline show great potential. One such candidate is expected to have fewer side effects and could potentially be used in combination with other GLP-1 drugs to further enhance efficacy. Metsera stated that it plans to initiate late-stage clinical trials for this drug later this year. Analysts estimate that if these products are ultimately approved, their annual sales could reach billions of dollars. This acquisition is not just about a single asset; it also reflects the strategic positioning of pharmaceutical giants in the highly promising obesity drug market, which some analysts estimate could reach $150 billion by the early next decade.
The market is closely watching to see how this battle among giants over the next generation of weight-loss therapies will conclude.
